Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Nature Medicine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm971PMID 14702637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation.

  2002cited by this paper
• Maintenance of Differentiated Phenotype of Articular Chondrocytes by Protein Kinase C and Extracellular Signal-regulated Protein Kinase*

  2002cited by this paper
• STAT 1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF 2

  2001cited by this paper
• STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2.

  2001cited by this paper
• Present Status of the Use of Growth Hormone in Short Children with Bone Diseases (Diseases of the Skeleton)

  2001cited by this paper
• Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury.

  2001cited by this paper
• Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures

  2001cited by this paper
• Dwarfism and early death in mice lacking C-type natriuretic peptide

  2001cited by this paper
• Mechanical and physicochemical regulation of the action of insulin-like growth factor-I on articular cartilage.

  2000cited by this paper
• Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

  2000cited by this paper
• Regulation of Fetal Rat Bone Growth by C-Type Natriuretic Peptide and cGMP

  2000cited by this paper
• FGF signals for cell proliferation and migration through different pathways.

  2000cited by this paper
• Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways.

  2000cited by this paper
• Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3).

  1999cited by this paper
• FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway.

  1999cited by this paper
• Reciprocal Antagonism Coordinates C-type Natriuretic Peptide and Mitogen-signaling Pathways in Fibroblasts*

  1999cited by this paper
• The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system.

  1999cited by this paper
• Distraction osteogenesis for lengthening of the tibia in patients who have limb-length discrepancy or short stature.

  1999cited by this paper
• Natriuretic peptide regulation of endochondral ossification : evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway

  1999cited by this paper
• Distraction Osteogenesis of the Lower Extremity with Use of Monolateral External Fixation. A Study of Two Hundred and Sixty-one Femora and Tibiae*

  1998cited by this paper
• Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide.

  1998cited by this paper
• Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3.

  1998cited by this paper
• Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.

  1998cited by this paper
• Natriuretic Peptide Regulation of Endochondral Ossification

  1998cited by this paper
• Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model.

  1997cited by this paper
• Short-limb skeletal dysplasias and craniosynostosis: what do they have in common?

  1997cited by this paper
• Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor

  1996cited by this paper
• Fibroblast growth factor receptor 3 is a negative regulator of bone growth.

  1996cited by this paper
• Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase II

  1996cited by this paper
• Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3

  1996cited by this paper
• Molecular biology and biochemistry of the natriuretic peptide system

  1996cited by this paper
• A synthetic inhibitor of the mitogen-activated protein kinase cascade.

  1995cited by this paper
• Achondroplasia is defined by recurrent G380R mutations of FGFR3.

  1995cited by this paper
• Insulin-like growth factor 1 and parathyroid hormone effects on the growth of fetal rat metatarsal bones cultured in serum-free medium.

  1995cited by this paper
• Developmental expression of a type II collagen/β‐galactosidase fusion gene in transgenic mice

  1995cited by this paper
• Opposite effects of osteogenic protein and transforming growth factor β on chondrogenesis in cultured long bone rudiments

  1994cited by this paper
• Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

  1994cited by this paper
• Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): comparison with the human CNP gene (NPPC).

  1994cited by this paper
• Non-radioisotopic quantitative RT-PCR to detect changes in mRNA levels during early mouse embryo development.

  1993cited by this paper
• Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors.

  1992cited by this paper
• Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system.

  1992cited by this paper
• Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides.

  1992cited by this paper
• Longitudinal bone growth in vitro: effects of insulin-like growth factor I and growth hormone.

  1991cited by this paper
• Guanylate cyclase receptor family.

  1990cited by this paper
• Cloning and sequence analysis of a cDNA encoding a precursor for rat C‐type natriuretic peptide (CNP)

  1990cited by this paper
• Physiological role of silent receptors of atrial natriuretic factor.

  1987cited by this paper
• Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine.

  1979cited by this paper

• Efficacy and safety of Vosoritide in achondroplasia: A systematic review and meta-analysis

  2026cites this paper
• Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential.

  2026cites this paper
• Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling

  2026cites this paper
• Identification of Surrogate Biomarkers for Mucopolysaccharidosis Type IVA

  2025cites this paper
• Investigation of serum C-type natriuretic peptide concentration at diagnosis and remission in pediatric osteosarcomas

  2025cites this paper
• Celebrating the 100th anniversary of the Japan Endocrine Society: reflecting on my 50 years of hormone research

  2025cites this paper
• Real-world safety and age-dependent effectiveness of vosoritide in achondroplasia: A single-center retrospective analysis of transition from growth hormone to vosoritide.

  2025cites this paper
• Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report.

  2025cites this paper
• TACC3 facilitates chondrocyte differentiation by attenuating abnormally activated FGFR3 signaling in achondroplasia - An in vitro study.

  2025cites this paper
• Phosphodiesterase 3 inhibitors boost bone outgrowth

  2025cites this paper
• C-type natriuretic peptide as mediator of growth in the absence of growth hormone: Unraveling the mystery of the growth without GH syndrome.

  2025cites this paper
• A nonsense mutation in the PRKG2 gene in dalmatian dogs with chondrodysplasia

  2025cites this paper
• C-Type Natriuretic Peptide Analogs: Current and Future Therapeutic Applications

  2024cites this paper
• Promising horizons in achondroplasia along with the development of new drugs.

  2024cites this paper
• C-type natriuretic peptide (CNP): The cardiovascular system and beyond.

  2024cites this paper
• Achondroplasia: aligning mouse model with human clinical studies shows crucial importance of immediate postnatal start of the therapy

  2024cites this paper
• Advances in the mechanism and therapies of achondroplasia

  2024cites this paper
• Neprilysin inhibition promotes skeletal growth via the CNP/NPR-B pathway.

  2024cites this paper
• The Principle of Cortical Development and Evolution

  2024cites this paper
• Progress in managing children with achondroplasia

  2024cites this paper
• ERK signaling expands mammalian cortical radial glial cells and extends the neurogenic period

  2024cites this paper
• Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.

  2024cites this paper
• Radiological characteristics of skeletal growth in neonates and infants with achondroplasia

  2023cites this paper
• ERK signaling drives evolutionary expansion of the mammalian cerebral cortex

  2023cites this paper
• Is a boost to height a boost to health? Dwarfism therapies spark controversy

  2023cites this paper
• Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial

  2023cites this paper
• Novel therapeutic perspectives in Noonan syndrome and RASopathies

  2023cites this paper
• Pharmacological and Genetic Disruption of C-Type Natriuretic Peptide (nppcl) Expression in Zebrafish (Danio rerio) Causes Stunted Growth during Development

  2023cites this paper
• Guanylyl cyclase/natriuretic peptide receptor-A: Identification, molecular characterization, and physiological genomics

  2023cites this paper
• Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide

  2022cites this paper
• Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood

  2022cites this paper
• Novel Treatment Options in Childhood Bone Diseases

  2022cites this paper
• Broadening the Spectrum of Loss-of-Function Variants in NPR-C-Related Extreme Tall Stature

  2022cites this paper
• Natural history of clinical features in two brothers with acromesomelic dysplasia related to PRKG2

  2022cites this paper
• C-type Natriuretic Peptide–induced PKA Activation Promotes Endochondral Bone Formation in Hypertrophic Chondrocytes

  2022cites this paper
• Collagen X Marker Levels are Decreased in Individuals with Achondroplasia

  2022cites this paper
• Cranial Base Synchondrosis: Chondrocytes at the Hub

  2022cites this paper
• Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts

  2022cites this paper
• Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study.

  2022cites this paper
• Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP

  2022cites this paper
• Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth

  2021cites this paper
• Mechanical load regulates bone growth via periosteal Osteocrin.

  2021cites this paper
• Evolution of the membrane/particulate guanylyl cyclase: from physicochemical sensors to hormone receptors.

  2021cites this paper
• Improved maturation competence of ovarian tissue oocytes using a biphasic in vitro maturation system for patients with gynecological malignancy: a study on sibling oocytes

  2021cites this paper
• Development of the skeleton

  2021cites this paper
• Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

  2021cites this paper
• Prevention of guanylyl cyclase–B dephosphorylation rescues achondroplastic dwarfism

  2021cites this paper
• Guanylyl cyclase‐A phosphorylation decreases cardiac hypertrophy and improves systolic function in male, but not female, mice

  2021cites this paper
• The heart, an endocrine gland: natriuretic peptides.

  2021cites this paper
• Expanding horizons of achondroplasia treatment: current options and future developments.

  2021cites this paper
• Emerging therapies for Achondroplasia: changing the rules of the game

  2021cites this paper
• Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia

  2021cites this paper
• C-type natriuretic peptide and its contribution to bone growth.

  2021cites this paper
• Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia

  2021cites this paper
• C-type natriuretic peptide facilitates autonomic Ca2+ entry in growth plate chondrocytes for stimulating bone growth

  2021cites this paper
• Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis

  2021cites this paper
• Endocrinology of Bone and Growth Disorders

  2021cites this paper
• Role of NPR2 mutation in idiopathic short stature: Identification of two novel mutations

  2020cites this paper
• Role of Signal Transduction Pathways and Transcription Factors in Cartilage and Joint Diseases

  2020cites this paper
• Association of TMEM8B and SPAG8 with Mature Weight in Sheep

  2020cites this paper
• Biallelic cGMP-dependent type II protein kinase gene (PRKG2) variants cause a novel acromesomelic dysplasia

  2020cites this paper
• Overview of Skeletal Development.

  2020cites this paper
• C-type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII.

  2020cites this paper
• Novel therapeutic approaches for the treatment of Achondroplasia.

  2020cites this paper
• Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.

  2020cites this paper
• The phosphatase inhibitor LB-100 acts synergistically with the NPR2 agonist BMN-111 to improve bone growth

  2020cites this paper
• Short Stature is Progressive in Patients with Heterozygous NPR2 Mutations.

  2020cites this paper
• A Review of the Pharmacological Properties of Psoralen

  2020cites this paper
• C-type natriuretic peptide stimulates osteoblastic proliferation and collagen-X expression but suppresses fibroblast growth factor-23 expression in vitro

  2020cites this paper
• Fibroblast growth factor (FGF) and FGF receptor families in bone

  2020cites this paper
• Thyroid and Bone

  2020cites this paper
• Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia

  2020cites this paper
• Growth plate gene involment and isolated short stature

  2020cites this paper
• C-type natriuretic peptide (CNP)/Guanylate cyclase B (GC-B) system and endothelin-1(ET-1)/ET receptor A and B system in human vasculature.

  2020cites this paper
• New developments in the management of achondroplasia

  2020cites this paper
• A novel nonsense mutation in NPR2 gene causing Acromesomelic dysplasia, type Maroteaux in a consanguineous family in Southern Punjab (Pakistan)

  2020cites this paper
• Is C-type natriuretic peptide regulated by a feedback loop? A study on systemic and local autoregulatory effect

  2020cites this paper
• Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength.

  2020cites this paper
• Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias

  2019cites this paper
• Achondroplasia: a comprehensive clinical review

  2019cites this paper
• Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment

  2019cites this paper
• Analogs of C-type natriuretic peptide as a potential new non-surgical treatment strategy in knee osteoarthritis.

  2019cites this paper
• The evolving therapeutic landscape of genetic skeletal disorders

  2019cites this paper
• Periosteum-derived Osteocrin regulates bone growth through both endochondral ossification and intramembranous ossification

  2019cites this paper
• Genetic Ablation and Guanylyl Cyclase/Natriuretic Peptide Receptor-A: Impact on the Pathophysiology of Cardiovascular Dysfunction

  2019cites this paper
• Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids

  2019cites this paper
• Translational science: Newly emerging science in biology and medicine — Lessons from translational research on the natriuretic peptide family and leptin —

  2019cites this paper
• Achondroplasia

  2019cites this paper
• Natriuretic peptides in human heart: Novel insight into their molecular forms, functions, and diagnostic use.

  2019cites this paper
• C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.

  2019cites this paper
• Fibroblast growth factors in skeletal development.

  2019cites this paper
• Mechanistic insights into skeletal development gained from genetic disorders.

  2019cites this paper
• ÖGEKM / ÖGR PATIENT SATISFACTION AND DISEASE ACTIVITY INDICES IN RHEUMATOID ARTHRITIS PATIENTS

  2019cites this paper
• Pseudoacromegaly.

  2019cites this paper
• Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth

  2019cites this paper
• C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.

  2019cites this paper
• Title Rats deficient C-type natriuretic peptide suffer from impairedskeletal growth without early death

  2018cites this paper
• Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death

  2018cites this paper
• Nitric oxide and cyclic GMP functions in bone.

  2018cites this paper
• Thyroid Hormone and Skeletal Development.

  2018cites this paper